mounjaro tirzepatide news today september 2025 Eli Lilly temporarily halts UK shipments of weight-loss drug Both good news & bad

Hillier, R

No finished-product clinical trial on AlkaLean was identified during the review process

As previously mentioned in the Legal framework section, in contrast to FDA, EMA has no authority to issue the drug approvals

While compounded medications are not FDA-approved, the pharmacies that make them must follow all relevant regulatory guidelines to ensure quality and safety

descriptive statistics were evaluated using the safety analysis set (participants exposed to the trial product) and statistical analyses were based on the full analysis set

The well-documented association between metabolic conditions, such as type 2 diabetes mellitus (T2DM) and obesity, and the risk of dementia has created opportunities for repurposing metabolic drugs for neurological disorders (Long and Holtzman, 2019)